Member Info for daveycaferacer

Yet again our Company delivers on its strategy and financials, exceeding forecasts on revenue, EBITDA and profit by considerable margin. Pipeline development accelerating, we are close to fulfilling our goal as a leading China and eventually global drug Company.

Not only am I expecting a very strong performance again, but I'd like to see further updates on the pipeline shortly. Fruquintinib must be very close to a NDA submission and with forecast shared sales in excess of $1bn it could add significant revenue and profits by 2017/2018. Also expecting a further update on the other property compensation deal and more milestone payments from Astra, Lilly and Nestle all coming.

Excellent fund, THANKYOU twonks

Our IPO seems to be taking longer than usual for NASDQ

Despite the current market turmoil there is still a lot of money in the U.S. markets and Biotechs are considered by many to be the best of a bad bunch, along with tech stocks. As Beigiene's IPO was successful there is nothing to suggest ours won't be either.

Beigene share price up over 50% since IPO two days ago This is a very good sign for us

Beigene = big IPO and tiny pipeline I do not think we will have too much of a problem getting our IPO bearing in mind our pipeline depth and the fact we have a number of candidates in or about to go in to Phase III

looks like they got it away a day early........thanks for the update Team!

Looks like Beigene will begin trading on Thursday if their $151m NASDAQ IPO gets away I'm surprised we've not had a further update on ours by now, should be getting something as we filed our initial registration statement on the 21st August. Beigene filed on the 28th August so that gives an indication.

Agree 100% Matt earnings will be what matters. I've looked at Edisons last research note saying 33 cents by 2018 but the Company always beats forecasts and that figure doesn't factor in any drug sales from the pipeline. We could have 3 or 4 in production by then so that figure could multiplied many times

haha Matt, no, I did get the irony, I'll admit to being a very big fan of HCM and how they are cleverly expanding their Business by using the cash generated by the commercial division to fund the Innovation division drug development. 35% revenue growth per annum? I think that is conservative - it was 100% last year, 90% the year before, forecast to be circa 50% this year, and that is without having sold a single drug from the development pipeline. Independent Analysts expect sales could exceed $2bn p.a by 2018, possibly even more when Savolitinib, Frquintinib and Sulfatinib get launched. Conservative $2bn (taking into account partners) x Average price to sales of 13.51 = $27bn = £18bn so £12bn is a very conservative estimate Now some people may say yes, but not all drug candidates will be successful and make it through Phase III to launch but the circa $2bn forecast sales is only for the top 3 candidates, there are 5 others and the Commercial platforms revenues have almost doubled in the last 3 years and are forecast to be $941m by 2018 with 50% attributable to Chi-Med

Sure, this will be a £12bn mcap Company in 10 years time with annual sales in excess of £2bn, based on pipeline and that's just the Innovation part of the Business, IMO, DYOR etc etc etc

It will be £190 in 10 years time IMO so I took continue to buy more

20% drop in a week is unprecedented for Hutchison China Meditech Is there some intel the NASDAQ IPO is delayed due to the state of the markets or some other issue? It'll be interesting to see if Beigene's IPO gets off the ground next week, although they're a lot smaller with a very small pipeline. I wonder if the state of the China markets down 20% since the beginning of the year is having an effect.....

Looks like Beigene's IPO has been priced and the number of ADR's set. Based on their timeline ours should follow very shortly.

NASDAQ IPO update due plus closure of property compensation (funds received) Updates due on multiple drug candidates Plus there is an absolute frenzy of acquisition activity in the sector (Shire/Baxalta) and many others The sector shows no signs of slowing down and with the imminent NASDAQ IPO our Company's profile will be at an enhanced level amongst some U.S. Institutional Investors.

I agree, and Savolitinib results should be good because all results have been very encouraging so far - we could get Breakthrough therapy designation in the U.S. in 2016 for PRCC Targeting existing $6bn sales for the specific targets including c-met, T-790 and EGFRm and we could end up with a very large chunk of that market (shared with AZ). We will also get more milestone payments from AZ on Savolitinib in 2016 Also due more updates on Fruquintinib soon with potential Beakthrough Therapy designation in Sept 2016. Phase III study due to complete in China in early 2016 - potential $1 billion in annual sales for this drug alone The complete stable of drugs in stage II and III has potential of $5 billion in annual sales which could be a reality in 5 or 6 years time

Very large buy today, generally a lot more buying than selling recently Next big news NASDAQ IPO I'd like to see another research note. However, as the Company's shares are tightly held by Hutchison, HCM Directors and a mall mumber of institutions there's not much incentive to commission research. Those already invested know what's in store and the Comiany's prospects over the next decade

I had a very large holding with an average buy price of 210p and sold the lot for 450p - what a major mistake Now have a large holding and continue to buy every month This Company is a master at building Shareholder value over the long term and is a unique long term investment IMO The pipeline is looking very strong and the Company's track record of development is superb. No major drug candidates have been dropped In the 2012 Annual Report they demonstrated that a competitor whose drugs moved into Phase III trials were were worth circa $540m NPV PER CANDIDATE. WE have a number of candidates moving into Phase III over the next couple of years. All the hard work of our Company will richly reward loyal Shareholders over the next 10 years. Also nice to see HWL and all Directors have never sold a share.....ever

Very good points. I think Biophrama/Biotechs seem to have done quite well over the past year and there does appear to be an appetite for some people to move out of natural resources and get a better return on their capital. Tech and Biotech seems to be where the money is flowing.